Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2026-02-17 Annual Report (ESEF)
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Document d'enregistrement universel 2025
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-02-17 English
Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la 
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Teva announcing positive Phase IIb clinical trial results for their drug candidate, duvakitug. It details study methodology, efficacy data, and safety profiles, and discusses the implications for their ongoing Phase III programs. It does not constitute a formal financial report, a regulatory filing, or a shareholder meeting document. As it is a corporate announcement regarding research and development progress, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-02-17 French
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Earnings Release Classification · 95% confidence The document is a press release issued by Sanofi and Teva announcing positive clinical trial results (Phase 2b) for their investigational drug 'duvakitug'. It details study methodology, efficacy endpoints, and safety data. This type of announcement, which provides updates on clinical development progress and pipeline status, is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement regarding business operations and R&D milestones that does not fit into more specific categories like earnings releases or financial reports. FY 2026
2026-02-17 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and contains tables detailing share repurchase activities by Sanofi. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2026-02-16 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and explicitly states that Sanofi is declaring purchases of its own shares for a specific period (8 February 2020 to 12 February 2020). It includes a table detailing transaction volumes and weighted average prices. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2026-02-16 English
Communiqué de presse : L’étude sur Beyfortus publiée dans la revue The Lancet Infectious Diseases montre ses bénéfices chez les nourrissons au-delà de la première saison du VRS
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the publication of clinical study results for their product 'Beyfortus' in the medical journal 'The Lancet Infectious Diseases'. It details the study's findings, methodology, and implications for public health. It does not constitute a formal financial report, proxy statement, or regulatory filing required by an exchange, but rather a corporate communication regarding product research and development. As it does not fit into specific categories like 10-K, IR, or ER, and is a general corporate announcement, it is classified as a Regulatory Filing (RNS).
2026-02-16 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.